U.S.News & World Report
Yale-New Haven Hospital has been named as one of the top hospitals in the United States, according to
U.S.News & World Report's
annual "America's Best Hospitals" rankings. In the cancer services category, Yale-New Haven is ranked 23rd in the country. We have had a significant improvement in our reputation scores over the last year and will continue our efforts to raise the reputation score, while continuing to review and monitor other segments that affect our ranking.
Anees Chagpar Appointed Director of the Yale Breast Center
I am pleased to announce that Dr. Anees Chagpar will join the surgery faculty at Yale School of Medicine in the section of breast surgery beginning September 1st. Anees is nationally recognized for her continued efforts in breast cancer care and research. Her leadership and clinical expertise will complement the exceptional clinical care offered in the Women's Health Center and greatly benefit patients with breast cancer at Smilow Cancer Hospital. Please join me in welcoming Anees to Yale Cancer Center.
Karen Anderson Named Co-Director of DT Program
The Yale Cancer Center Executive Committee appointed Karen S. Anderson, PhD as Co-Director of our Developmental Therapeutics Research Program. Karen will lead the program along with Yung-Chi (Tommy) Cheng, PhD. Karen is a Professor of Pharmacology at Yale School of Medicine and has been an integral member of Yale Cancer Center throughout her 20-year career at Yale.
Joint YCC UCL Retreat a Success
13 members of Yale Cancer Center traveled to the University College London last week to participate in their annual scientific retreat and present research from Yale Cancer Center. I appreciate the time and commitment made by the attendees from YCC and look forward to reviewing potential areas of collaboration resulting from the meetings. Please continue to share your ideas for new ways we can strengthen the alliance and benefits of partnership with UCL.
SCH Town Hall
I hope you will join Abe Lopman and me for a Smilow Cancer Hospital Town Hall meeting on
Wednesday, July 28th
at noon in the Park Street Auditorium for an update and discussion on the progress of clinical care and program development. The work continues to successfully transition all of the clinical cancer care to Smilow Cancer Hospital and we value your input and suggestions.
Established in 1996, the
Yale Cancer Center Director's Advisory Board
is a group of volunteers who share a commitment to YCC and help it accomplish its mission. The group meets twice a year, provides counsel to the YCC Director and its leadership, and assists in its fundraising and advocacy efforts. At the spring meeting, five new members were welcomed to the Board: Cara Balogh, Jim Jacobs, John de Neufville, Laurel Schwartz, and Michael Silverberg.
Current Board Members:
Kathryn Anderson Adams - Greenwich, CT
Cara Balogh - Miami, FL
Duke Brodsky - Fairfield, CT
Louis Chênevert - Farmington, CT
George Crapple - Greenwich, CT
Blythe Danner - New York, NY
John de Neufville - Mendham, NJ
G.S. Beckwith Gilbert - Greenwich, CT
Jim Jacobs - Avon, CT
Paul Kelly - Westport, CT
Nicholas Makes - Southport, CT
Jack Mitchell - Wilton, CT
Harold Parmelee - New Canaan, CT
Joseph Perella - New York, NY
Stephen Riker - New York, NY
Richard S. Sackler, MD - Greenwich, CT
Laurel Schwartz - Westport, CT
Michael Silverberg - Essex, CT
Jim Vlock - Woodbridge, CT
Paula Zahn - New York, NY
The Yale Cancer Center Clinical Trials Office has recently hired the following staff members to help meet the needs and requirements of our clinical research operations:
- Senior Administrative Assistant
- Clinical Trial Assistant
Maria Slade, RN
- Research Nurse
- Data Manager
Burroughs Wellcome Fund Career Awards For Medical Scientists
For medically-trained scientists who will have completed at least 2 years, but not more than 120 months of postdoctoral research training by October 1, 2010.
Awards provide bridging support for 1-2 years of advanced postdoctoral training and the initial 3-4 years of a faculty appointment.
Promise Grants seek to support integrated programs of collaborative and cross-disciplinary research projects leading to the aggressive translation of scientific discoveries into interventions and strategies that have the greatest potential to significantly reduce breast cancer incidence and/or mortality.
Applicants may request funding for 5 years: Up to $6,500,000 over the timeframe of the grant.
AACR Judah Folkman Fellowship for Anti-Angiogenesis Research
This Fellowship is open to Postdoctoral and Clinical Research Fellows with a medical degree or a combined MD/PhD working at an academic, medical, or research institution who will be in the first 5 years of their postdoctoral training at the start of the grant term. Proposed research projects are restricted to basic, clinical, translational or epidemiological projects that substantially advance the field of anti-angiogenesis research in cancer. One 2-year grant of $90,000 ($45,000 per year) will be awarded.
AACR Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway
This Career Development Award is open to junior faculty who have completed their postdoctoral studies or clinical fellowship no more than 4 years before the start of the grant term. Proposed research projects must have direct applicability to the HER Family Pathway (basic, translational, clinical, or epidemiological cancer research). One 2-year grant of $100,000 ($50,000 per year) will be awarded.
Alex's Lemonade Stand Foundation 'A' Award for Young Researchers in Pediatric Oncology
The 'A' Award is a three-year grant designed for young scientists who want to jump-start their career in pediatric oncology research. The ideal candidate has an original project which is not currently being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application. The goals of the 'A' Award Program are to: 1) encourage the best and brightest young researchers to build a life-long career and become a leader in the pediatric cancer field, and 2) further research that will lead to cures or impact children with cancer.